This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (80)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Roger J. Porter, MD; Robert B. Layzer, MD

Arch Neurol. 1975;32(5):298-303.

Abstract
The plasma protein binding of diphenylhydantoin sodium wad determined In 26 patients who had been taking diphenylhydantoin regularly for more than two weeks. The free (unbound) diphenylhydantoin level was found to vary from 5.8% to 12.6% of the total drug concentration. This range of variation may be clinically important, if it can be established that the binding of diphenylhydantoin to plasma proteins limits entry of the drug into the brain. The binding of diphenylhydantoin was directly proportional to the plasma albumin concentration, which thus appeared to be the most important determinant of diphenlhydantoin binding. Diphenylhydantoin binding was independent of the plasma concentration of the drug in the usual therapeutic range. In vitro studies showed little effect by phenobarbital sodium or penicillin G; therapeutic levels of acetylsalicylic acid, however, increased free diphenylhydantoin by nearly 50%.

Author Affiliations
From the Department of Neurology, University of California School of Medicine, San Francisco. Dr. Porter is now at the Applied Neurologic Research Branch of the National Institutes of Health, Bethesda, Md.

Footnotes
Accepted for publication July 30, 1974.

Read in part before the 99th annual meeting of the American Neurological Association, Boston, June 10, 1974.

Reprint requests to Applied Neurologic Research Branch, Bldg 36, Room 5D-10, National Institutes of Health, Bethesda, MD 20014 (Dr. Porter).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

DIFFERENCES IN THE PHARMACOKINETICS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS IN GENETICALLY OBESE ZUCKER AND SPRAGUE-DAWLEY RATS: IMPLICATIONS OF DECREASED GLUCURONIDATION IN OBESE ZUCKER RATS
Kim et al.
Drug Metab. Dispos. 2004;32:909-914.
ABSTRACT | FULL TEXT  

Variability of Phenytoin Protein Binding in Epileptic Patients
DeMonaco and Lawless
Arch Neurol 1983;40:481-483.
ABSTRACT  

Serum Phenytoin Concentrations in Uremia
BURGESS et al.
ANN INTERN MED 1981;94:59-60.
ABSTRACT  

Maintenance of Therapeutic Phenytoin Plasma Levels via Intramuscular Administration
PERRIER et al.
ANN INTERN MED 1976;85:318-321.
ABSTRACT